Oestrogen receptor (ER) positive breast cancer

Indication for Goserelin

Population group: Suitable for women, only adults (18 years old or older)
  • Advanced breast cancer in pre and perimenopausal women suitable for hormonal manipulation.
  • Goserelin is indicated as an alternative to chemotherapy in the standard of care for pre/perimenopausal women with oestrogen receptor (ER) positive early breast cancer.

For this indication, competent medicine agencies globally authorize below treatments:

3.6 mg once every 28 days

Route of admnistration

Subcutaneous

Defined daily dose

3.6 - 3.6 mg

Dosage regimen

From 3.6 To 3.6 mg once every 28 day(s)

Detailed description

One 3.6 mg depot of goserelin injected subcutaneously into the anterior abdominal wall, every 28 days.

Active ingredient

Goserelin is a synthetic analogue of naturally occurring LHRH. On chronic administration goserelin results in inhibition of pituitary LH secretion leading to a fall in serum testosterone concentrations in males and serum estradiol concentrations in females.

Read more about Goserelin

Related medicines

Summary of Product Characteristics (SPC) 2017: ZOLADEX Implant, in pre-filled syringe

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner